Dr. Reddy's Laboratories Ltd (RDY)

ADS Common

Sell: $12.86|Buy: $13.49|Change: 0.14 (1.06%)

Open

$13.30

Previous close

$13.15

Trade high

$13.36

Volume

2,007,810

Year high

$15.71

Year low

$12.185

Dividend yield

0.69%

Market capitalisation

$11.07 bn

P/E ratio

24.53

ISIN

US2561352038

This share can be held in a Dealing account SIPP

Share price

Dividends

	Previous	Latest
Record date	10/07/2025	09/07/2026
Ex-dividend date	25/07/2025	09/07/2026
Payment date	06/08/2025	Invalid date
Amount	$0.09149	$0.08336

Performance 18/06/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Dr. Reddy's Laboratories Ltd	+ 1.06
More...

Company profile

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%).Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand nameand earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Sector

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.